• Grand Pharmaceutical clarified its proposed replacement of HLB with Deloitte reflects overseas expansion needs requiring a larger auditor with broader international coverage.
• The need emerged during August-October 2026 audit preparations, following HLB's reappointment at the June annual general meeting.
• Deloitte's proposed appointment for the year ending December 31, 2026, remains subject to shareholder approval.
• At least 20 personnel would undertake the audit, with completion targeted for March 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261103-12398148), on November 03, 2026, and is solely responsible for the information contained therein.